Market cap
$377 Mln
Revenue (TTM)
$58 Mln
P/E Ratio
--
P/B Ratio
15.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.2
-
Debt to Equity
1.3
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
52,758,200
10 Years Aggregate
CFO
$-652.69 Mln
EBITDA
$-738.80 Mln
Net Profit
$-768.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
| 134.4 | 0.6 | 167.8 | 364.3 | -22.8 | -28.0 | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
| -43.8 | -46.8 | -43.2 | -31.9 | 38.0 | -3.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout G1 Therapeutics (GTHX)
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers... COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. Read more
-
CEO, President & Director
Mr. John E. Bailey Jr.
-
CEO, President & Director
Mr. John E. Bailey Jr.
-
Headquarters
Research Triangle Park, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for G1 Therapeutics (GTHX)
What is the current share price of G1 Therapeutics Inc (GTHX) Today?
The share price of G1 Therapeutics Inc (GTHX) is $7.15 (NASDAQ) as of 18-Sep-2024 09:30 EDT. G1 Therapeutics Inc (GTHX) has given a return of -22.82% in the last 3 years.
What is the current PB & PE ratio of G1 Therapeutics Inc (GTHX)?
Since, TTM earnings of G1 Therapeutics Inc (GTHX) is negative, P/E ratio is not available.
The P/B ratio of G1 Therapeutics Inc (GTHX) is 15.34 times as on 18-Sep-2024, a 277 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-3.31
|
4.48
|
|
2022
|
-1.62
|
3.48
|
|
2021
|
-2.89
|
-0.73
|
|
2020
|
-6.89
|
-1.57
|
|
2019
|
-8.01
|
-2.90
|
What is the 52 Week High and Low of G1 Therapeutics Inc (GTHX)?
The 52-week high and low of G1 Therapeutics Inc (GTHX) are Rs -- and Rs -- as of 22-May-2026.
What is the market cap of G1 Therapeutics Inc (GTHX)?
G1 Therapeutics Inc (GTHX) has a market capitalisation of $ 377 Mln as on 18-Sep-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in G1 Therapeutics Inc (GTHX)?
Before investing in G1 Therapeutics Inc (GTHX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.